Loading...
In 1970, the FDA categorized psilocybin as a Schedule 1 drug, largely because of its recreational uses, which include inducing spirituality and synesthesias (e.g., seeing music, hearing art). More recently, several trials of this serotonin 2A agonist have supported further research into its use for treatment-resistant major depressive disorder (MDD; NEJM JW Psychiatry Jul 2017 and Neuropsychopharmacology 2017; 42:2105). The current researchers administered psilocybin to 19 medication-free participants with MDD (mean age, 42; 21% women).
Two-time dosing was once at 10 mg, followed 1 week later with 25 mg. Functional magnetic resonance imaging (fMRI)occurred at baseline and post-treatment at 1 day after the 25-mg dose — to capture “afterglow” …